Exelixis Company Leadership
| EXEL Stock | USD 45.60 0.81 1.81% |
Exelixis employs about 1.1 K people. The company is managed by 17 executives with a total tenure of roughly 70 years, averaging almost 4.0 years of service per executive, having 67.47 employees per reported executive. Inspection of Exelixis' management performance can provide insight into the company performance.
| Michael Morrissey CEO CEO and President and Director |
| Stelios Papadopoulos Chairman Chairman and Member of Audit Committee |
Exelixis Management Team Effectiveness
The company has return on total asset (ROA) of 0.1805 % which means that it generated a profit of $0.1805 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3022 %, meaning that it created $0.3022 on every $100 dollars invested by stockholders. Exelixis' management efficiency ratios could be used to measure how well Exelixis manages its routine affairs as well as how well it operates its assets and liabilities.Exelixis Workforce Comparison
Exelixis is rated # 5 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 15,641. Exelixis holds roughly 1,147 in number of employees claiming about 7% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.28 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.34 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.34. Exelixis Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Exelixis insiders, such as employees or executives, is commonly permitted as long as it does not rely on Exelixis' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Exelixis insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Wyszomierski Jack L over a month ago Disposition of 7535 shares by Wyszomierski Jack L of Exelixis at 43.09 subject to Rule 16b-3 | ||
Smith Julie over a month ago Acquisition by Smith Julie of 9812 shares of Exelixis subject to Rule 16b-3 | ||
Heyman Tomas J. over two months ago Disposition of 4544 shares by Heyman Tomas J. of Exelixis at 44.29 subject to Rule 16b-3 | ||
Haley Patrick J. over two months ago Disposition of 34387 shares by Haley Patrick J. of Exelixis at 44.06 subject to Rule 16b-3 | ||
Smith Julie over three months ago Acquisition by Smith Julie of 19294 shares of Exelixis at 19.77 subject to Rule 16b-3 | ||
Christopher Senner over three months ago Acquisition by Christopher Senner of 29314 shares of Exelixis at 18.8 subject to Rule 16b-3 | ||
Smith Julie over three months ago Disposition of 31167 shares by Smith Julie of Exelixis at 20.5 subject to Rule 16b-3 | ||
Hessekiel Jeffrey over three months ago Disposition of 18134 shares by Hessekiel Jeffrey of Exelixis at 35.0 subject to Rule 16b-3 |
Exelixis Notable Stakeholders
An Exelixis stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Exelixis often face trade-offs trying to please all of them. Exelixis' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Exelixis' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael Morrissey | CEO and President and Director | Profile | |
| Stelios Papadopoulos | Chairman and Member of Audit Committee | Profile | |
| Susan Hubbard | Executive Vice President - Public Affairs and Investor Relations | Profile | |
| Christopher Senner | CFO, Executive Vice President | Profile | |
| Peter Lamb | Chief Scientific Officer and Executive VP of Discovery Research | Profile | |
| Stefan Krauss | VP Development | Profile | |
| Laura Dillard | Executive Resources | Profile | |
| Tony Redmond | Senior Resources | Profile | |
| Gregg Bernier | VP Marketing | Profile | |
| William MD | Senior Affairs | Profile | |
| Amy MD | Executive Officer | Profile | |
| Patrick MBA | Executive Commercial | Profile | |
| Dana Aftab | Executive Officer | Profile | |
| Jeffrey JD | Executive Counsel | Profile | |
| Anne MD | Senior Safety | Profile | |
| Andrew Peters | Senior Strategy | Profile | |
| MBA MBA | Ex Commercial | Profile |
About Exelixis Management Performance
The success or failure of an entity such as Exelixis often depends on how effective the management is. Exelixis management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Exelixis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Exelixis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California. Exelixis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 954 people.
Exelixis Workforce Analysis
Traditionally, organizations such as Exelixis use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Exelixis within its industry.Exelixis Manpower Efficiency
Return on Exelixis Manpower
| Revenue Per Employee | 1.9M | |
| Revenue Per Executive | 127.6M | |
| Net Income Per Employee | 454.5K | |
| Net Income Per Executive | 30.7M | |
| Working Capital Per Employee | 927.5K | |
| Working Capital Per Executive | 62.6M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.